Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Nov;52(10):e13759.
doi: 10.1111/and.13759. Epub 2020 Jul 21.

Efficiency of intracavernosal alprostadil and oral clomiphene citrate combination treatment in penile vasculogenic erectile dysfunction patients accompanied by late-onset hypogonadism

Hakan Hakkı Taşkapu  1 , Mehmet Giray Sönmez  1 , Muzaffer Tansel Kılınç  1 , Nurullah Altınkaya  1 , Arif Aydın  1 , Mehmet Balasar  1
Affiliations

Efficiency of intracavernosal alprostadil and oral clomiphene citrate combination treatment in penile vasculogenic erectile dysfunction patients accompanied by late-onset hypogonadism

Hakan Hakkı Taşkapu et al. Andrologia. 2020 Nov.

Abstract

In this study, the efficiency of intracavernosal alprostadil + oral clomiphene citrate (CC) treatment in late-onset hypogonadism (LOH) accompanied by penile vasculogenic erectile dysfunction (PVED) in patients irresponsive to phosphodiesterase type 5 inhibitor treatment was evaluated. A total of 31 patients with concurrent PVED and LOH were included in the study. The patients were given intracavernosal alprostadil (10-20 μg) and oral CC (50 mg) every day for 12 weeks. Before and after treatment, a 15-question International Index of Erectile Function (IIEF-15) questionnaire, Erection Hardness Score (EHS), Sexual Encounter Profile (SEP)2 and SEP3 levels were analysed, and follicle stimulating hormone (FSH), luteinising hormone (LH), total testosterone and prostate-specific antigen (PSA) levels were measured. In all, 41.9% of patients had pure arterial deficiency, 19.3% had pure venous deficiency, and 38.7% had arterial + venous (mixed) deficiency. A significant increase was detected in total testosterone, FSH, LH and PSA values after treatment when compared to values before treatment (p < .001, p < .001, p < .001 and p = .034 respectively). A significant recovery was observed in IIEF-15 subscores, EHS and SEP2-SEP3 results. In PVED patients accompanied by LOH, intracavernosal alprostadil and oral CC combination is an efficient, low cost, safely applicable and tolerable treatment.

Keywords: alprostadil; clomiphene citrate; erectile dysfunction; hypogonadism; intracavernosal treatment.

PubMed Disclaimer

References

REFERENCES

    1. Bella, A. J., Lee, J. C., Carrier, S., Benard, F., & Brock, G. B. (2015). 2015 CUA practice guidelines for erectile dysfunction. Canadian Urological Association Journal, 9(1–2), 23–29.
    1. Burnett, A. L., Nehra, A., Breau, R. H., Culkin, D. J., Faraday, M. M., Hakim, L. S., … Shindel, A. W. (2018). Erectile dysfunction: AUA guideline. The Journal of Urology, 200(3), 633–641. https://doi.org/10.1016/j.juro.2018.05.004
    1. Buvat, J., Costa, P., Morlier, D., Lecocq, B., Stegmann, B., & Albrecht, D. (1998). Double‐blind multicenter study comparing alprostadil alpha‐cyclodextrin with moxisylyte chlorhydrate in patients with chronic erectile dysfunction. Urology, 1159, 116–119.
    1. Corona, G., Rastrelli, G., Forti, G., & Maggi, M. (2011). Update in testosterone therapy for men. The Journal of Sexual Medicine, 8, 639–654.
    1. Duncan, C., Omran, G. J., The, J., Davis, N. F., Bolton, D. M., & Lawrentschuk, N. (2019). Erectile dysfunction: A global review of intracavernosal injectables. World Journal of Urology, 37(6), 1007–1014. https://doi.org/10.1007/s00345‐019‐02727‐5